CODA Biotherapeutics

CODA Biotherapeutics shut down in March 2023 after pursuing gene therapies for neurological diseases like focal epilepsy. ​​‌‌‌‌‌‌‌​‌‌​​‌​​​​​​‌‌​‌‌‌​​​‌‌The company targeted a genuine problem: patients with severe epilepsy had limited treatment options, with roughly 30% experiencing drug-resistant seizures. This population experienced the problem acutely—uncontrolled seizures caused injury, sudden death, and profound quality-of-life degradation. The condition was measurable through seizure frequency and EEG readings. Existing alternatives included pharmaceutical management, surgical intervention, and vagus nerve stimulation, though these had significant limitations. CODA's failure revealed critical warning signs. The company pursued an extraordinarily complex technical pathway—gene therapy for the brain requires crossing the blood-brain barrier and achieving precise neuronal targeting. Development timelines stretched longer than anticipated, and manufacturing challenges mounted. Despite backing from Versant and MPM Capital, CODA apparently underestimated both the technical difficulty and capital requirements needed to reach clinical proof-of-concept. The startup had solved a real problem but chose a solution whose complexity exceeded its resources and runway.